Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Tipranavir

Insgesamt 75 ergebnisse

NCT00486330

Abgeschlossen

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir

Bedingungen: HIV Infections
NCT00344123

Abgeschlossen

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

Bedingungen: HIV Infections
NCT00062660

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Bedingungen: HIV Infections
NCT00146328

Abgeschlossen

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Bedingungen: HIV Infections
NCT00607958

Abgeschlossen

Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours

Bedingungen: HIV Infections
NCT00933205

Approved for marketing

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Bedingungen: HIV Infections
NCT02244190

Abgeschlossen

Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

Bedingungen: Healthy
NCT00275444

Abgeschlossen

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Bedingungen: HIV Infections
NCT02253797

Abgeschlossen

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

Bedingungen: Healthy
NCT00144287

Abgeschlossen

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

Bedingungen: HIV Infections
NCT00615290

Abgeschlossen

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Bedingungen: HIV Infections
NCT02251795

Abgeschlossen

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Bedingungen: Healthy
NCT00034866

Abgeschlossen

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

Bedingungen: HIV Infections
NCT02226991

Abgeschlossen

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Bedingungen: Healthy
NCT00530920

Abgeschlossen

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Bedingungen: HIV Infections
NCT02257021

Abgeschlossen

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

Bedingungen: Healthy
NCT00144170

Abgeschlossen

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Bedingungen: HIV Infections
NCT00097799

Approved for marketing

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Bedingungen: HIV Infections
NCT02238314

Abgeschlossen

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

Bedingungen: HIV Infections
NCT02253875

Abgeschlossen

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Bedingungen: Healthy
NCT02251145

Abgeschlossen

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

Bedingungen: Healthy
NCT00531206

Abgeschlossen

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Bedingungen: HIV Infections
NCT00976950

Abgeschlossen

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Bedingungen: HIV Infections
NCT00054717

Abgeschlossen

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Bedingungen: HIV Infections
NCT02251158

Abgeschlossen

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Bedingungen: Healthy